BT-483 Xenograft Model Service for Breast Cancer

The BT-483 xenograft model represents a sophisticated in vivo tool for studying hormone-receptor-positive (ER+/PR+) breast cancer, offering a high-fidelity platform to evaluate endocrine therapies and overcome clinical resistance. As a leading oncology CRO, Alfa Cytology delivers precision-driven BT-483 xenograft services, ensuring that your drug discovery program is backed by robust, clinically relevant data.

Overview of BT-483 Xenograft Model for Breast Cancer

The BT-483 xenograft model is derived from a human breast adenocarcinoma cell line originally isolated from a pleural effusion. It is a prototypical representative of the Luminal A subtype, characterized by strong expression of the Estrogen Receptor (ER) and Progesterone Receptor (PR), while remaining HER2-negative.

Unlike more aggressive, hormone-independent models, BT-483 exhibits a strictly estrogen-dependent growth pattern in vivo. To ensure successful tumor engraftment and consistent growth kinetics, the host animals must be supplemented with exogenous 17β-estradiol. This requirement allows researchers to precisely model the effects of estrogen deprivation or competitive inhibition. The BT-483 model is widely utilized to evaluate Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), and Aromatase Inhibitors (AIs), providing critical evidence for transitioning novel endocrine therapies from the bench to the clinic.

Fig 1. Cancer-related pathway and cytokine activity in human breast cancer cell lines. (Jin H, et al., 2023)

Cell Line Information: BT-483

Our Services

Workflow of BT-483 Xenograft Model Construction

The construction of a BT-483 xenograft model at Alfa Cytology follows a rigorous, standardized workflow:

• Cell Preparation: BT-483 cells are cultured in vitro using optimized, hormone-stripped media. Cells are harvested during the exponential growth phase to ensure maximum viability.
• Animal Conditioning: Female immunocompromised mice (e.g., Balb/c Nude or SCID) are prepared. A controlled-release 17β-estradiol pellet is surgically implanted to establish a pro-tumorigenic hormonal environment.
• Inoculation: A high-concentration cell suspension, often enriched with an extracellular matrix (Matrigel), is injected subcutaneously or orthotopically into the mammary fat pad.
• Tumor Monitoring: After a brief latency period, tumor volumes are monitored via digital calipers. Animal health and body weights are tracked 2-3 times per week to establish a growth curve.
• Randomization & Dosing: Once tumors reach a pre-defined mean volume, animals are randomized into homogeneous groups to ensure statistical parity before the therapeutic regimen commences.

Fig 2. BT-483 Xenograft Model Construction Workflow

Case Study - BT-483 Xenograft Model Development

In a recent preclinical program, Alfa Cytology established the BT-483 xenograft model to evaluate a novel Selective Estrogen Receptor Degrader (SERD). By utilizing precise 17β-estradiol supplementation and orthotopic implantation, we achieved a consistent tumor take rate and predictable growth kinetics. The study demonstrated significant tumor growth inhibition (TGI) in the treatment group, with endpoint in vivo analysis confirming the dose-dependent degradation of the Estrogen Receptor, providing essential proof-of-concept data for our client's regulatory filing.

Why Choose Alfa Cytology?

• Hormonal Modeling Expertise: Specialized protocols for establishing and managing strictly hormone-dependent tumors.
• Technical Precision: Expertise in orthotopic fat pad inoculation to better mimic the natural breast microenvironment.
• Integrated Analysis: Full support for PK/PD profiling and detailed analysis of receptor expression levels.
• Standardized Facilities: All studies are conducted in modern, strictly controlled animal facilities using authenticated cell lines to ensure data integrity.

Contact Us

Ready to explore the therapeutic potential of your endocrine agents with a high-fidelity BT-483 model? Our oncology experts are standing by to discuss your study design and provide a tailored project proposal. Please reach out to us today to learn more about our services, or contact us directly to initiate your next in vivo breakthrough with Alfa Cytology.

For research use only. Not intended for any clinical use.